We recently traveled to Salt Lake City, Utah for a State of the Science Summit™ on Non–Small Cell Lung Cancer. At the meeting, faculty from the University of Utah and Intermountain Healthcare, delved into biomarker discoveries, research regarding the heredity of lung cancer, emerging treatment modalities, and practice-changing trials that have impacted the paradigm. Other topics included the role of immunotherapy and exciting combinations that are generating excitement in this space as well as novel drugs that are revolutionizing the treatment of patients with NSCLC whose tumors harbor ROS1 or ALK mutations.